Trial Profile

Phase II/III trial of TNX 4800 for Lyme disease

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 15 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TNX 4800 (Primary)
Indications Lyme disease
Focus Therapeutic Use

Most Recent Events

30 Dec 2025 According to a Tonix Pharmaceuticals media release, company shows intention to meet with the US FDA to explore phase II/III development options of TNX 4800, in 2026 and available for clinical trials in early in 2027.
10 Nov 2025 According to a Tonix Pharmaceuticals media release, the company is plans to initiate the adaptive study during tick season in 2027.
06 Nov 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com